Search
Votucalis
go.drugbank.com/drugs/DB05032InvestigationalrEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Lacidipine
go.drugbank.com/drugs/DB09236ApprovedIt is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … Lacidipine is a highly lipophilic molecule that interacts with the biological membranes.
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalOtamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
Categories: Factor Xa InhibitorsMitoxantrone
go.drugbank.com/drugs/DB01204ApprovedInvestigationalAn anthracenedione-derived antineoplastic agent.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexProducts: MITOXANTRONE BAXTER SOLUTION FOR INJECTION 20MG/10ML (2MG/ML)XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
BHV-1300
go.drugbank.com/drugs/DB22673InvestigationalBHV-1300 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.
Crenolanib
go.drugbank.com/drugs/DB11832InvestigationalCrenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.
Dutogliptin
go.drugbank.com/drugs/DB11723InvestigationalDutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalApproved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral